Anti-Sp17 monoclonal antibody with antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity activities against human ovarian cancer cells

Medical Oncology

Volumn 29, Issue 4, 2012, Pages 2923-2931

  Song, Jia Xi ^a   Cao, Wang Li ^a   Li, Fang Qiu ^a   Shi, Li Ning ^a   Jia, Xuan ^a  

^a NANJING UNIVERSITY   (China)

Author keywords

Anti Sp17 monoclonal antibody; Antibody dependent cell mediated cytotoxicity; Complement dependent cytotoxicity; Ovarian cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CANCER TESTIS ANTIGEN; MONOCLONAL ANTIBODY SPERM PROTEIN 17; SPERM PROTEIN 17; UNCLASSIFIED DRUG;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; DRUG BINDING; HUMAN; HUMAN CELL; MONOCYTE; OVARY CANCER; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, SURFACE; CARRIER PROTEINS; CELL LINE, TUMOR; COMPLEMENT SYSTEM PROTEINS; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; HUMANS; OVARIAN NEOPLASMS;

EID: 84867990152     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-011-0137-0     Document Type: Article

References (44)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA: Cancer J Clincians. 2010;60(5):277-300.
2. Kristedja TS, Morgan RJ, Cristea M. Targeted agents in ovarian cancer. Women's Health (London, England). 2010;6(5):679-94.
3. Polakis P. Arming antibodies for cancer therapy. Curr Opin Pharmacol. 2005;5(4):382-7.
4. O'Rand MG, Widgren EE, Fisher SJ. Characterization of the rabbit sperm membrane autoantigen, RSA, as a lectin-like zona binding protein. Dev Biol. 1988;129(1):231-40.
5. Kong M, Richardson RT, Widgren EE, O'Rand MG. Sequence and localization of the mouse sperm autoantigenic protein, Sp17. Biol Reprod. 1995;53(3):579-90.
6. Lea IA, Kurth B, O'Rand MG. Immune response to immunization with sperm antigens in the macaque oviduct. Biol Reprod. 1998;58(3):794-800.
7. Lea IA, Richardson RT, Widgren EE, O'Rand MG. Cloning and sequencing of cDNAs encoding the human sperm protein, Sp17. Biochim Biophys Acta. 1996;1307(3):263-6.
8. McLeskey SB, Dowds C, Carballada R, White RR, Saling PM. Molecules involved in mammalian sperm-egg interaction. Int Rev Cytol. 1998;177:57-113.
9. Lacy HM, Sanderson RD. Sperm protein 17 is expressed on normal and malignant lymphocytes and promotes heparan sulfate-mediated cell-cell adhesion. Blood. 2001;98(7):2160-5.
10. Lim SH, Wang Z, Chiriva-Internati M, Xue Y. Sperm protein 17 is a novel cancer-testis antigen in multiple myeloma. Blood. 2001;97(5):1508-10.
11. Grizzi F, Gaetani P, Franceschini B, Di Ieva A, Colombo P, Ceva-Grimaldi G, et al. Sperm protein 17 is expressed in human nervous system tumours. BMC Cancer. 2006;6:23.
12. Straughn JM Jr, Shaw DR, Guerrero A, Bhoola SM, Racelis A, Wang Z, et al. Expression of sperm protein 17 (Sp17) in ovarian cancer. Int J Cancer. 2004;108(6):805-11.
13. Li FQ, Han YL, Liu Q, Wu B, Huang WB, Zeng SY. Overexpression of human sperm protein 17 increases migration and decreases the chemosensitivity of human epithelial ovarian cancer cells. BMC Cancer. 2009;9:323.
14. Li FQ, Liu Q, Han YL, Wu B, Yin HL. Sperm protein 17 is highly expressed in endometrial and cervical cancers. BMC Cancer. 2010;10:429.
15. Liu Q, Li FQ, Han YL, Wang LK, Hou YY. Aberrant expression of sperm protein 17 enhances migration of ovarian cancer cell line HO-8910. Nat J Androl. 2008;14(11):982-6.
16. Chiriva-Internati M, Weidanz JA, Yu Y, Frezza EE, Jenkins MR, Kennedy RC, et al. Sperm protein 17 is a suitable target for adoptive T-cell-based immunotherapy in human ovarian cancer. J Immunother. 2008;31(8):693-703.
17. Chiriva-Internati M, Yu Y, Mirandola L, Jenkins MR, Chapman C, Cannon M, et al. Cancer testis antigen vaccination affords long-term protection in a murine model of ovarian cancer. PloS one. 2010;5(5):e10471.
18. Li FQ, Zhang SX, An LX, Gu YQ. In vivo Molecular targeting effects of anti-Sp17- ICG-Der-02 on hepatocellular carcinoma evaluated by an optical imaging system. J Exp Clin Cancer Res. 2011;30:25.
19. Nimmerjahn F, Ravetch JV. Antibodies, Fc receptors and cancer. Curr Opin Immunol. 2007;19(2):239-45.
20. Natsume A, Niwa R, Satoh M. Improving effector functions of antibodies for cancer treatment: enhancing ADCC and CDC. Drug Design Dev Ther. 2009;3:7-16.
21. Li FQ, Yang AL, Miao JW, Zhang CH, Wu B, Zhang XH. Preparation and characterization of the monoclonal antibody against human sperm protein 17. Chin J Cellular Molecul Immunol. 2006;22(5):638-40.
22. Lin Y, Peng S, Yu H, Teng H, Cui M. RNAi-mediated downregulation of NOB1 suppresses the growth and colony-formation ability of human ovarian cancer cells. Medical Oncol (Northwood, London, England). 2011: [Epub ahead of print].
23. Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nat Biotechnol. 2005;23(9):1147-57.
24. Richardson RT, Yamasaki N, O'Rand MG. Sequence of a rabbit sperm zona pellucida binding protein and localization during the acrosome reaction. Dev Biol. 1994;165(2):688-701.
25. Grizzi F, Chiriva-Internati M, Franceschini B, Hermonat PL, Soda G, Lim SH, et al. Immunolocalization of sperm protein 17 in human testis and ejaculated spermatozoa. J Histochem Cytochem. 2003;51(9):1245-8.
26. Wen Y, Richardson RT, Widgren EE, O'Rand MG. Characterization of Sp17: a ubiquitous three domain protein that binds heparin. Biochem J. 2001;357(Pt 1):25-31.
27. Grizzi F, Chiriva-Internati M, Franceschini B, Bumm K, Colombo P, Ciccarelli M, et al. Sperm protein 17 is expressed in human somatic ciliated epithelia. J Histochem Cytochem. 2004;52(4):549-54.
28. Chiriva-Internati M. Sperm protein 17: clinical relevance of a cancer/testis antigen, from contraception to cancer immunotherapy, and beyond. Int Rev Immunol. 2011;30(2-3):138-49.
29. Zhang Y, Wang Z, Robinson WR, Lim SH. Combined real time PCR and immunohistochemical evaluation of sperm protein 17 as a cancer-testis antigen. Eur J Haematol. 2004;73(4):280-4.
30. Pisani F, Maini CL, Sciuto R, Dessanti L, D'Andrea M, Assisi D, et al. FCR (Fludarabine, Cyclophosphamide, Rituximab) regimen followed by 90Yttrium ibritumomab tiuxetan consolidation for the treatment of relapsed grades 1 and 2 follicular lymphoma: a report of 9 cases. J Exp Clin Cancer Res. 2011;30:16.
31. Idusogie EE, Presta LG, Gazzano-Santoro H, Totpal K, Wong PY, Ultsch M, et al. Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc. J Immunol. 2000;164(8):4178-84.
32. Crowe JS, Hall VS, Smith MA, Cooper HJ, Tite JP. Humanized monoclonal antibody CAMPATH-1H: myeloma cell expression of genomic constructs, nucleotide sequence of cDNA constructs and comparison of effector mechanisms of myeloma and Chinese hamster ovary cell-derived material. Clin Exp Immunol. 1992;87(1):105-10.
33. Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 2008;84(5):548-58.
34. Lencer WI, Blumberg RS. A passionate kiss, then run: exocytosis and recycling of IgG by FcRn. Trends Cell Biol. 2005;15(1):5-9.
35. Lazar GA, Dang W, Karki S, Vafa O, Peng JS, Hyun L, et al. Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci USA. 2006;103(11):4005-10.
36. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood. 2002;99(3):754-8.
37. Cartron G, Watier H, Golay J, Solal-Celigny P. From the bench to the bedside: ways to improve rituximab efficacy. Blood. 2004;104(9):2635-42.
38. Geis N, Zell S, Rutz R, Li W, Giese T, Mamidi S, et al. Inhibition of membrane complement inhibitor expression (CD46, CD55, CD59) by siRNA sensitizes tumor cells to complement attack in vitro. Curr Cancer Drug Targ. 2011;10(8):922-31.
39. Hourcade D, Liszewski MK, Krych-Goldberg M, Atkinson JP. Functional domains, structural variations and pathogen interactions of MCP, DAF and CR1. Immunopharmacology. 2000;49(1-2):103-16.
40. Davies A, Lachmann PJ. Membrane defence against complement lysis: the structure and biological properties of CD59. Immunol Res. 1993;12(3):258-75.
41. Donin N, Jurianz K, Ziporen L, Schultz S, Kirschfink M, Fishelson Z. Complement resistance of human carcinoma cells depends on membrane regulatory proteins, protein kinases and sialic acid. Clin Exp Immunol. 2003;131(2):254-63.
42. Niwa R, Sakurada M, Kobayashi Y, Uehara A, Matsushima K, Ueda R, et al. Enhanced natural killer cell binding and activation by low-fucose IgG1 antibody results in potent antibody-dependent cellular cytotoxicity induction at lower antigen density. Clin Cancer Res. 2005;11(6):2327-36.
43. Gelderman KA, Kuppen PJ, Okada N, Fleuren GJ, Gorter A. Tumor-specific inhibition of membrane-bound complement regulatory protein Crry with bispecific monoclonal antibodies prevents tumor outgrowth in a rat colorectal cancer lung metastases model. Cancer Res. 2004;64(12):4366-72.
44. Hong F, Yan J, Baran JT, Allendorf DJ, Hansen RD, Ostroff GR, et al. Mechanism by which orally administered beta-1, 3-glucans enhance the tumoricidal activity of antitumor monoclonal antibodies in murine tumor models. J Immunol. 2004;173(2):797-806.